Swiss National Bank Purchases 10,300 Shares of GoodRx Holdings, Inc. $GDRX

Swiss National Bank grew its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 6.4% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 171,700 shares of the company’s stock after purchasing an additional 10,300 shares during the period. Swiss National Bank’s holdings in GoodRx were worth $757,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Hohimer Wealth Management LLC boosted its stake in shares of GoodRx by 8.2% in the 1st quarter. Hohimer Wealth Management LLC now owns 35,218 shares of the company’s stock worth $155,000 after buying an additional 2,658 shares during the last quarter. SBI Securities Co. Ltd. boosted its stake in shares of GoodRx by 13.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company’s stock worth $100,000 after buying an additional 2,748 shares during the last quarter. Gotham Asset Management LLC boosted its stake in shares of GoodRx by 31.0% in the 4th quarter. Gotham Asset Management LLC now owns 17,677 shares of the company’s stock worth $82,000 after buying an additional 4,182 shares during the last quarter. Citizens Financial Group Inc. RI purchased a new position in shares of GoodRx in the 1st quarter worth approximately $44,000. Finally, Headlands Technologies LLC boosted its stake in shares of GoodRx by 213.2% in the 1st quarter. Headlands Technologies LLC now owns 14,830 shares of the company’s stock worth $65,000 after buying an additional 10,095 shares during the last quarter. 63.77% of the stock is owned by institutional investors.

GoodRx Price Performance

GoodRx stock opened at $4.33 on Wednesday. GoodRx Holdings, Inc. has a 12 month low of $3.31 and a 12 month high of $8.80. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.75. The business’s 50 day simple moving average is $4.58 and its 200 day simple moving average is $4.50. The company has a market cap of $1.50 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 1.85 and a beta of 1.24.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The firm had revenue of $203.07 million during the quarter, compared to analysts’ expectations of $205.72 million. During the same quarter in the previous year, the company posted $0.08 EPS. GoodRx’s revenue for the quarter was up 1.2% on a year-over-year basis. Sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Insider Transactions at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business’s stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total transaction of $51,249.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.17% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on GDRX shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $6.00 target price on shares of GoodRx in a research note on Monday, August 11th. Wells Fargo & Company cut their target price on GoodRx from $8.00 to $7.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 29th. The Goldman Sachs Group cut their target price on GoodRx from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Friday, May 9th. Raymond James Financial downgraded GoodRx from a “strong-buy” rating to an “outperform” rating in a research note on Friday, August 8th. Finally, UBS Group dropped their price objective on GoodRx from $6.00 to $5.25 and set a “neutral” rating on the stock in a research note on Tuesday, May 13th. Five investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $5.80.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.